THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION…
MaaT PharmaNovember 14, 2025
MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor…
MaaT PharmaNovember 5, 2025
MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update The…
MaaT PharmaNovember 4, 2025
MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected…
MaaT PharmaNovember 3, 2025
MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial…
MaaT PharmaOctober 7, 2025
MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update Positive results…
MaaT PharmaSeptember 17, 2025
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step…
MaaT PharmaJuly 28, 2025
MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux Lyon, France, July 24,…
MaaT PharmaJuly 24, 2025
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaJuly 7, 2025
